

Appl. No. 09/854,811  
Amdt. dated May 13, 2009  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1642

PATENT

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-52. (Canceled)

Claim 53. (Currently amended) A method for inducing a cellular immune response in a human subject directed to a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, the subject having a cancer overexpressing the PSCA protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject dendritic cells pulsed with the PSCA protein of SEQ ID NO:2 or pulsed with an immunogenic fragment of the PSCA protein of SEQ ID NO:2, wherein the immunogenic fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2 ~~consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.~~

Claims 54 to 57. (Canceled)

Claim 58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claims 59 to 77. (canceled).

Claim 78. (Currently amended) A method for inducing an immune response in a mammalian subject directed to a PSCA protein of SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of SEQ ID NO:2 or an immunogenic fragment thereof wherein the fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2, wherein dendritic

cells are used to present PSCA the protein or protein fragments to T cells in the context of MHC class I and II molecules.

Claim 79. (Previously presented) The method of claim 78 wherein the immune response is a humoral response, whereby an antibody is produced.

Claim 80. (Previously presented) The method of claim 78, wherein the subject is a human.

Claim 81. (Previously presented) The method of claim 78, wherein the subject is a sheep, rat, dog, cat, pig, horse, or mouse.

Claim 82. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claims 83 to 98. (canceled).

Claim 99. (Previously presented) The method of claim 53, wherein the cancer is prostate cancer, prostate cancer metastasized to bone.

Claim 100. (Previously presented) The method of claim 78, wherein the immune response is a humoral immune response.